[{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Obinutuzumab","moa":"||B-lymphocyte antigen CD20","graph1":"Nephrology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Ocrelizumab","moa":"||B-lymphocyte antigen CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Leiden University Medical Center","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Leiden University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leiden University Medical Center \/ ZonMw","highestDevelopmentStatusID":"10","companyTruncated":"Leiden University Medical Center \/ ZonMw"},{"orgOrder":0,"company":"Leiden University Medical Center","sponsor":"ZonMw | Gelre Hospitals | Maasstad Hospital | Maastricht University Medical Center | Medisch Spectrum Twente | HagaZiekenhuis","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"NETHERLANDS","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Leiden University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leiden University Medical Center \/ ZonMw | Gelre Hospitals | Maasstad Hospital | Maastricht University Medical Center | Medisch Spectrum Twente | HagaZiekenhuis","highestDevelopmentStatusID":"10","companyTruncated":"Leiden University Medical Center \/ ZonMw | Gelre Hospitals | Maasstad Hospital | Maastricht University Medical Center | Medisch Spectrum Twente | HagaZiekenhuis"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"Glucocorticoid receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"LifeMark Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"LifeMark Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"LifeMark Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"LifeMark Health \/ Undisclosed"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"Glucocorticoid receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unity Health Toronto \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Unity Health Toronto \/ Undisclosed"},{"orgOrder":0,"company":"Mercy Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Mercy Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mercy Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mercy Health \/ Undisclosed"},{"orgOrder":0,"company":"Rutgers University","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"Glucocorticoid receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Rutgers University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Rutgers University \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Rutgers University \/ Undisclosed"},{"orgOrder":0,"company":"Robert Wood Johnson Barnabas Health","sponsor":"Brielle Orthopedics | University Orthopedics Associates","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"Glucocorticoid receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II\/ Phase III","graph3":"Robert Wood Johnson Barnabas Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Robert Wood Johnson Barnabas Health \/ Brielle Orthopedics | University Orthopedics Associates","highestDevelopmentStatusID":"9","companyTruncated":"Robert Wood Johnson Barnabas Health \/ Brielle Orthopedics | University Orthopedics Associates"},{"orgOrder":0,"company":"Oklahoma Medical Research Foundation","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Oklahoma Medical Research Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oklahoma Medical Research Foundation \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Oklahoma Medical Research Foundation \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Novartis Pharmaceuticals Corporation | Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moffitt Cancer Center \/ Novartis Pharmaceuticals Corporation | Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Moffitt Cancer Center \/ Novartis Pharmaceuticals Corporation | Celgene Corporation"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Novartis Pharmaceuticals Corporation | Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moffitt Cancer Center \/ Novartis Pharmaceuticals Corporation | Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Moffitt Cancer Center \/ Novartis Pharmaceuticals Corporation | Celgene Corporation"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"Glucocorticoid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"Glucocorticoid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"Glucocorticoid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"Glucocorticoid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Perrigo Company plc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biogen \/ Perrigo Company plc","highestDevelopmentStatusID":"11","companyTruncated":"Biogen \/ Perrigo Company plc"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Teva Pharmaceutical Industries | University of Texas Health Science Center at Houston | University of Alabama at Birmingham | Charite University, Berlin, Germany","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ Teva Pharmaceutical Industries | University of Texas Health Science Center at Houston | University of Alabama at Birmingham | Charite University, Berlin, Germany","highestDevelopmentStatusID":"8","companyTruncated":"UT Southwestern Medical Center \/ Teva Pharmaceutical Industries | University of Texas Health Science Center at Houston | University of Alabama at Birmingham | Charite University, Berlin, Germany"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Patient-Centered Outcomes Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Patient-Centered Outcomes Research Institute","highestDevelopmentStatusID":"10","companyTruncated":"Mayo Clinic \/ Patient-Centered Outcomes Research Institute"},{"orgOrder":0,"company":"Jean Charles Doucet","sponsor":"Nova Scotia Health Authority","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"Glucocorticoid receptor","graph1":"Nephrology","graph2":"Phase IV","graph3":"Jean Charles Doucet","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jean Charles Doucet \/ Nova Scotia Health Authority","highestDevelopmentStatusID":"11","companyTruncated":"Jean Charles Doucet \/ Nova Scotia Health Authority"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Acquisition","leadProduct":"Methylprednisolone","moa":"||Lysosomal acid glucosylceramidase (GBA1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":1.04,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":1.04,"dosageForm":"Injection","sponsorNew":"Prevail Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"||Lysosomal acid glucosylceramidase (GBA1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Prevail Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Acquisition","leadProduct":"Methylprednisolone","moa":"||Lysosomal acid glucosylceramidase (GBA1)","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":1.04,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":1.04,"dosageForm":"Injection","sponsorNew":"Prevail Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"||Lysosomal acid glucosylceramidase (GBA1)","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Prevail Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"||PGRN","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Prevail Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Belimumab","moa":"||Tumor necrosis factor ligand superfamily member 13B","graph1":"Nephrology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Belimumab","moa":"||Tumor necrosis factor ligand superfamily member 13B","graph1":"Nephrology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Belimumab","moa":"||Tumor necrosis factor ligand superfamily member 13B","graph1":"Nephrology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Belimumab","moa":"||Tumor necrosis factor ligand superfamily member 13B","graph1":"Nephrology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Itacitinib","moa":"||Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"ONCOtherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"||Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Oncology","graph2":"Phase I","graph3":"ONCOtherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ONCOtherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ONCOtherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ONCOtherapeutics","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"||Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Oncology","graph2":"Phase I","graph3":"ONCOtherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ONCOtherapeutics \/ Incyte Corporation","highestDevelopmentStatusID":"6","companyTruncated":"ONCOtherapeutics \/ Incyte Corporation"}]
Find Clinical Drug Pipeline Developments & Deals for DSSTox_CID_3300
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
